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Fibrin sealant as a carrier for sustained delivery of antibiotics
Antibiyotiklerin uzun süreli ilaç salınımı için bir taşıyıcı olarak fibrin yapıştırıcı
Selçuk Kara1, Ahmet Vural2, Ahmet Unver2, Baran Gencer1, Hasan Ali Tufan1, Sedat Arikan1,Ismail Ersan1 
ÖZET
Amaç: Sık görülen oküler bakteri suşlarında antibiyotik-
lerin fibrin yapıştırıcıda etkinlik ve sürekli salınımlarının 
değerlendirilmesi.
Yöntemler: Vankomisin, seftazidim, moksilofloksasin ve 
lomeflokasasin disk şeklinde fibrin yapıştırıcılara katıldı. 
Her bir antibiyotik diski ve ilaçsız kontrol fibrin diski in-vitro 
olarak Stafilokok aureus, Stafilokok epidermidis, Strepto-
kok Pnömonia ve Psödomonas aeruginosa standart bak-
teri suşlarında test edildiler. 37°C’de 24 saatlik inkübas-
yon  sonrasında  diskler  yeni  bakteri  pleytlerine  transfer 
edildiler ve bu işlem her antibiyotik için üç kez tekrarlandı.
Bulgular: 24 saat sonra tüm antibiyotik diskleri saptana-
bilir etkinlik gösterdiler. Streptokok Pnömonia’nın ürediği 
pleytte vankomisin en uzun sureli (4 gün) etkinliğe sahipti. 
Moksilofloksasin diskleri S. aureus ve S. pnömonia için 3 
gün ve diğer suşlara 2 gün uzamış inhibisyon etkisi gös-
termiştir.
Sonuç: Fibrin yapıştırıcılar uzun süreli ilaç dağılımı sağ-
lamaktadırlar. Bu özellik antibiyotik yüklü fibrin pıhtıların 
erken postoperatif koruma ve tedavi için kullanışlı olabile-
ceğini göstermektedir.
Anahtar kelimeler: Fibrin yapıştırıcı, uzun sureli salınım, 
antibiyotik, ilaç dağılımı, bakteri
ABSTRACT
Objective: To evaluate the activity and sustained release 
of antibiotics from fibrin sealant against common strains 
of ocular bacteria.
Methods:  Vancomycin,  ceftazidime,  moxifloxacin  and 
lomefloxacin were incorporated into fibrin sealant in the 
shape of discs. Each antibiotic disc and control fibrin disc 
without drug was tested in vitro against standard bacte-
rial  strains  of  Staphylococcus  aureus,  Staphylococcus 
epidermidis, Streptococcus pneumoniae and Pseudomo-
nas aeroginosa. After 24 hours of incubation at 37 °C, 
the discs were transferred to new plates of bacteria and 
triplicated for each antibiotic.
Results: All antibiotic discs demonstrated detectable ac-
tivity after 24 hours. Vancomycin had the longest duration 
of activity (4 days) on the S. pneumonia grown plate. The 
moxifloxacin discs showed a prolonged inhibition of S. au-
reus and S. pneumonia for 3 days and inhibited the other 
strains for 2 days.
Conclusion:  Fibrin  sealants  provided  prolonged  drug 
delivery, which indicates that antibiotic-loaded fibrin clots 
could be useful for early ocular postoperative care and 
treatment. J Clin Exp Invest 2014; 5 (2): 194-199
Key words: fibrin sealant, sustained release, antibiotic, 
drug delivery, bacteria
INTRODUCTION
Topical  administration  of  ocular  antibiotics  is  the 
current  common  route  of  ocular  therapy.  Despite 
of its easy administration, there are problems with 
the  rapid  drainage  and  penetration  of  the  drugs 
[1]. Although, there are developments in relation to 
this  drug  route,  such  as  functionalized  polymers, 
peptides  and  nano-particles,  it  requires  repetitive 
administration or higher drug doses to achieve suf-
ficient concentration at the posterior segment [2-4]. 
Topical administration may lead to insufficient anti-
microbial effects, fluctuations in ocular drug concen-
trations and poor compliance because of frequent 
instillation [2,5]. Also, fortified antibiotics for severe 
ocular infections include higher concentration of the 
drugs.  In  contrast,  the  subconjunctival,  posterior 
sub-tenon, retrobulbar, intracameral and intravitreal 
injection of the drugs enables practitioners to ad-
minister less of the antibiotic. These drug delivery 
methods provide drug diffusion through sclera or vit-
reous for a prolonged time [6]. In addition recently 
numerous ophthalmic vehicles for anterior segment 
were  developed  and  there  is  also  growing  inter-
est in drug delivery systems to posterior segment Kara et al. Sustained release of antibiotics from fibrin sealant  195
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which obtain long-term sustained release of drugs 
[5,7].  Nowadays,  biodegradable  antibiotic  loaded 
nanoparticles and polymeric drug delivery devices 
are reported to be used as an alternative delivery 
method of ocular antibiotics [8,9]. However, these 
methods are not broadened. Other classic antibiotic 
delivery methods have some limitations like risk of 
endophthalmitis, retinal detachment, vitreous hem-
orrhage  and  cataract  in  intravitreal  injection,  low 
drug bioavailability and corneal toxicity in frequent 
topically administrations [10,11]. 
Fibrin  sealants  have  hemostatic  and  adhe-
sive properties, and have been used increasingly 
in general surgical procedures [12]. For the last 20 
years  also  ophthalmic  surgical  procedures  have 
been  employed  the  use  of  fibrin  sealants  for  su-
tureless technique of pterygium and drug delivery 
[13-15]. Two liquid components of the fibrin sealant 
are mixed to form a fibrin clot that is biocompatible, 
biodegradable and suitable for mixing with a drug 
[15,16]. Several drugs, such as chemotherapeutics, 
antimicrobials  and  growth  factors,  were  reported 
to be encapsulated with fibrin sealant [17-19]. Al-
though fibrin sealants have the potential to provide 
a  slow  release  system  for  antibiotic  chemothera-
py, the features of the chemotherapy drugs might 
change  the  biochemical  interactions  of  the  drug-
sealant mixture, resulting in variations in the drugs’ 
release times [20]. The sealant mixtures might also 
be affected by the products of pathogen bacteria, 
such as bacterial toxins and enzymes, which can 
degrade  the  fibrin  matrix  faster  and  release  the 
drug rapidly. The recent studies related to orthope-
dics and general surgery reported on the efficacy of 
a single antibiotic that was impregnated in a fibrin 
sealant against commonly seen pathogens [13,21]. 
Marone et al. have been demonstrated antibacterial 
activity of the release of the four ocular antibiotics 
from fibrin sealant [22]. However, Staphylococcus 
epidermidis was the only bacterial strain analyzed 
in their study. There is need to be examined the po-
tential for the delivery of antibiotics by fibrin sealant 
on more bacterial strains.
The aim of this study is to investigate the anti-
bacterial effect of common and new ocular applica-
ble antibiotics impregnated into fibrin clots against 
four  common  ocular  bacterial  pathogens  and  to 
monitor their sufficient antibacterial effect time.
METHODS
In this study lyophilized human fibrin (Tisseel Lyo ®, 
Baxter, Vienna, Austria), standard bacterial strains 
of Staphylococcus aureus ( ATCC 65389), Staphy-
lococcus  epidermidis  (ATCC  12218),  Streptococ-
cus pneumoniae (ATCC 49619) and Pseudomonas 
aeroginosa (ATCC 27853) and the antibiotics van-
comycin (Vancomycin ®, Abbott France S.A., Run-
gis Cedex, France), ceftazidime (Fortum ® , Glaxo-
SmithKline, Izmit, Turkey), moxifloxacin (Vigamox, 
Alcon, TX, USA) and lomefloxacin (Okacin, Novar-
tis, Istanbul, Turkey ) were used. To prepare the fi-
brin glue with antibiotics, a thrombin solution and 
antibiotic solution were mixed and this mixture was 
transferred to a flat-bottomed 96 well plate. Later, it 
was mixed with fibrin component which contains fi-
brinogen, factor XIII and aprotinin was prepared ac-
cording to the manufacturer’s instructions. The final 
antibiotic concentrations were determined based on 
the commonly used concentrations in the antibiotic 
discs. The final concentrations of the antibiotic fibrin 
clot discs were 30 µg for vancomycin and ceftazi-
dime and 5 µg for moxifloxacin and lomefloxacin. 
The dimensions of discs were 6 mm of diameter 
and 4 mm of height. The antimicrobial effects of the 
vancomycin,  ceftazidime,  moxifloxacin  and  lome-
floxacin including fibrin glue discs were tested by 
using the Kirby-Bauer disc diffusion method against 
S.  aureus,  S.  epidermidis,  S.  pneumoniae  and 
P.  aeroginosa  standard  bacterial  strains.  Freshly 
grown bacterial colonies were prepared as suspen-
sions equal to 0.5 McFarland turbidity and spread 
on Mueller-Hinton agar media, or 5% sheep blood 
agar  medium  for  S.  pneumoniae,  with  a  sterile 
swab. Vancomycin, ceftazidime, moxifloxacin  and 
lomefloxacin loaded fibrin discs and control fibrin 
discs without drug were placed on the plates. The 
plates were incubated for 24 hours at 37 °C and 
any antibiotic fibrin discs that were not completely 
dissolved were transferred to new medium plates. 
This process was repeated after 24, 48, 72 and 96 
hours. The diameter of the inhibition zones around 
the discs were measured daily and the average for 
the three discs was recorded. These experiments 
were performed triplicate and the mean values of 
inhibition zones were analyzed.
RESULTS
The antibacterial effects of all four antibiotics were 
detectable, and the drugs achieved similar inhibi-
tion zones during the triplicate experiments for each 
antibiotic-sealant disc after 24 hours (Table 1-4). No 
zone of inhibition was observed around the control 
fibrin discs without drug. The zone of inhibition in 
the S. epidermidis plate was measurable with moxi-Kara et al. Sustained release of antibiotics from fibrin sealant  196
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floxacin on the second day, but the others showed 
activity only for the first day. In the S. aureus plate, 
the moxifloxacin-loaded discs had detectable zones 
after 3 days. Prolonged antimicrobial activity for S. 
pneumonia was observed with vancomycin (4 days) 
and moxifloxacin (3 days) discs. On the P. aerogi-
nosa grown plate, all of the antibiotics except van-
comycin (which is not selective) were released from 
the sealant, inhibiting bacterial growth for a period 
of 2 days. The inhibition zone diameters of all antibi-
otic-loaded fibrin sealant discs that were detectable 
on the second day decreased approximately 50% 
or more after 24 hours. All fibrin clots dissolved after 
three days on the P. aeroginosa plate; the vanco-
mycin-loaded sealants also dissolved on all plates 
after four days.
Diameter of inhibition zone (mm)
Antibiotic  24 h 48 h 72 h 4 days
Moxifloxacin (5 µg) 23 10.66 ± 0.77 3.66 ± 0.47 0
Lomefloxacin (5 µg) 16.66 ± 0.47 0 0 0
Vancomycin (30 µg) 13.66 ± 0.47 0 0 0
Ceftazidime (30 µg) 22.33 ± 0.57 0 0 0
Table 1. Antibacterial activity of antibi-
otic loaded fibrin sealant discs against 
Staphylococcus  aureus  (average  of 
triplicate experiments)
Diameter of inhibition zone (mm)
Antibiotic  24 h 48 h 72 h 4 days
Moxifloxacin (5 µg) 21.66 ± 0.57 11.33 ± 1.52 0 0
Lomefloxacin (5 µg) 18 ± 1 0 0 0
Vancomycin (30 µg) 13.33 ± 0.57 0 0 0
Ceftazidime (30 µg) 24.33 ± 1.15 0 0 0
Table 2. Antibacterial activity of antibi-
otic loaded fibrin sealant discs against 
Staphylococcus  epidermidis  (average 
of triplicate experiments)
Diameter of inhibition zone (mm)
Antibiotic 24 h 48 h 72 h 4 days
Moxifloxacin (5 µg) 22.66 ± 0.57 7.66 ± 0.57 2 ± 1.73 0
Lomefloxacin (5 µg) 5.66 ± 0.57 0 0 0
Vancomycin (30 µg) 16.66 ± 0.57 14.66 ± 0.57 5.33 ± 4.61 2 ± 1.73
Ceftazidime (30 µg) 26 20.33 ± 0.57 0 0
Table 3. Antibacterial activity of antibi-
otic loaded fibrin sealant discs against 
Streptococcus  pneumoniae  (average 
of triplicate experiments)
Diameter of inhibition zone (mm)
Antibiotic 24 h 48 h 72 h 4 days
Moxifloxacin (5 µg) 20.33 ± 0.57 3.33 ± 0.57 0 0
Lomefloxacin (5 µg) 16.66 ± 0.57 0.63 ± 0.05 0 0
Vancomycin (30 µg) 0 0 0 0
Ceftazidime (30 µg) 24.66 ± 0.57 0.6 ± 0.1 0 0
Table 4. Antibacterial activity of antibi-
otic loaded fibrin sealant discs against 
Pseudomonas aeroginosa (average of 
triplicate experiments)Kara et al. Sustained release of antibiotics from fibrin sealant  197
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DISCUSSION
This study shows that fibrin sealant has the poten-
tial to be used as a sustained release vehicle for 
ocular drug delivery. Prolonged antibacterial activ-
ity was observed for all antibiotic-impregnated fibrin 
sealants, but the elution of all agents at a therapeu-
tic concentration decreased by 50% or more after 
24 hours. The bolus from the antibiotic-impregnated 
fibrin sealant was possibly released from the pe-
ripheral layers of the sealant on the first day, so the 
bolus might have been in a gel or liquid phase. Al-
though the proposed procedure must be optimized 
to sustain the release of antibiotics and to prevent 
the  initial  rapid  release,  this  study  demonstrates 
that antibiotic-impregnated fibrin sealants, particu-
larly  vancomycin  and  moxifloxacin-impregnated 
sealants, are useful for ocular postoperative care 
and the treatment of bacterial diseases via local ad-
ministration.
Tissue adhesives have been successfully used 
for about 30 years for their hemostatic and adhe-
sive properties [12,23,24]. After the FDA approved 
fibrin tissue adhesives in 1998, their spectrum of us-
age broadened. Recently, fibrin sealant was used 
in  the  ocular  surgery  of  pterygium,  strabismus, 
bleb  revision,  amnion  membrane  transplantation 
and keratoplasty [25-28]. Fibrin sealants include 2 
liquid components of fibrinogen and thrombin that 
must be mixed to form a fibrin clot at the site of the 
application [16]. The fibrin clot provides adhesion 
between  the  corresponding  tissues  and  has  the 
potential to depot a drug that can be incorporated 
in liquid components just before the clot formation 
[15]. Therefore, the accumulation of a drug in a fi-
brin clot makes it possible to use the clot as a drug 
delivery vehicle.
The most common pathogenic bacteria in ocu-
lar infections are S. aureus, S. pneumonia, S. epi-
dermidis and P. aeroginosa [29]. Higher doses of 
effective antibiotics are useful for prophylaxis or for 
the treatment of ocular infections that they can be 
applied only locally with the minimum side effects 
and less frequency of administration. The delivery 
and activity of the four commonly used antibacteri-
als released from fibrin sealant were tested for ocu-
lar infections.
Although fibrin sealants have previously been 
used to deliver chemotherapeutics to tumor sites, 
the number of reports about the encapsulation and 
slow  release  of  antibiotics  from  sealants  has  re-
cently increased [21]. Simpson at al. showed that 
a carboplatin-impregnated fibrin sealant maintained 
a two-week drug release, whereas Tredwell at al. 
reported a mere 2-day release of cefazolin [13,19]. 
Therefore, a drug’s ability to depot in a fibrin sealant 
matrix and its elution from the sealant is possibly 
related to the drug’s interaction with the fibrin mate-
rial. Some studies recently demonstrated that hy-
drophobic antibiotics release from the sealant over 
the course of a week, whereas hydrophilic ones re-
lease in a shorter time [13,20,21]. Antibiotics used 
in this study also were hydrophilic drugs that may 
accelerate the elution of drugs. On the other hand, 
the elution time of antibiotic-loaded fibrin sealants 
may change as the pathogen bacteria change the 
environmental conditions. Bacterial toxins, bacterial 
enzymes and the antimicrobial responses of organ-
isms can affect the release time of the antibiotics 
from the sealant. In Marone at al.’s study, the anti-
bacterial activity of vancomycin-impregnated fibrin 
sealant persisted for 2 days on the S. aureus grown 
plate [22]. The present study likewise recorded a 
short activity time for S. aureus (one day) but In 
contrast, the antibacterial activity time extended to 
4 days on the S. pneumonia grown plate. Thus, the 
difference in this release time possibly comes from 
the fibrinolytic effects of S. aureus toxins. In the cur-
rent study, all of the antibiotic-fibrin sealant mixtures 
were  completely  dissolved  on  the  P.  aeroginosa 
grown plate at the end of the fourth day. Therefore, 
it can be suggested that the release time of the an-
tibiotic from fibrin sealant may be associated with 
the environment of the local treatment site. Quicker 
fibrinolysis of antibiotic loaded-fibrin sealant hinders 
the sealant’s ability to retain the drug, thus eradicat-
ing the slow release. However, at least 2 days of 
persistent antibacterial activity from a drug-loaded 
fibrin sealant might be enough to inhibit sensitive 
pathogenic  bacteria  for  early  postoperative  care. 
This  prolonged,  local  treatment  of  antibiotics  can 
also decrease the frequency of topical application 
so that the local dose is stable and so that practitio-
ners do not need to touch the eye lids often. After 
the local treatment period, topical therapy at a lower 
frequency should be started for maintenance.
There are some limitations to this study; the 
elution of the antibiotic-impregnated sealants in liq-
uid was not tested, so the authors do not know the 
real quantity of the released antibiotic from sealants, 
even in the cases where the antibiotic is still in the 
core of the sealant on the plate. In vivo, releasing 
times may increase because of the resultant drug. 
Moreover, the present study did not incorporate dif-
ferent concentrations of the antibiotics in the fibrin 
sealant, which might change the releasing times, Kara et al. Sustained release of antibiotics from fibrin sealant  198
J Clin Exp Invest   www.jceionline.org   Vol 5, No 2, June 2014
so further studies should be designed to discover 
which drug concentrations do not inhibit clot forma-
tion.
The present data indicate that the moxifloxa-
cin release over minimal inhibitory concentrations 
(MIC) from fibrin sealant is sufficient for three days 
against S. aureus and S. pneumonia grown plates. 
The inhibition zones of moxifloxacin were measured 
after at least two days for all bacterial isolates test-
ed. Moxifloxacin might be preferable for antibiotic-
impregnated fibrin sealants for ocular empiric treat-
ment or for postoperative care. The other antibiotics 
tested in this study may be used after the pathogen 
has  been  determined.  A  sensitive,  controlled-re-
lease antibiotic, such as vancomycin, seems to be 
effective against S. pneumonia.
The results of this study demonstrate that an-
tibiotic delivery through a sustained release system 
of fibrin sealant may be effective against common 
ocular  infections  in  vitro.  Especially,  moxifloxacin 
impregnated fibrin sealant in the environments of 
four  common  ocular  pathogens  suggests  that  it 
possibly has potential to be effective for one or two 
days longer than the other antibiotics studied, which 
might be useful for early ocular postoperative care 
and treatment.
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